

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8356349

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name			Execution Date
CALLIDITAS THERAPEUTICS AB			12/27/2023
RECEIVING PARTY DATA			
Name:	ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, AS ADMINISTRATIVE AGENT		
Street Address:	505 FIFTH AVENUE, FLOOR 18		
City:	NEW YORK		
State/Country:	NEW YORK		
Postal Code:	10017		
PROPERTY NUMBERS Total: 5			
Property Type	Number		
Patent Number:	8491932		
Application Number:	63302226		
Application Number:	63302216		
Application Number:	18100396		
Application Number:	18352811		
CORRESPONDENCE DATA			
Fax Number:	(704)339-5800		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7043311000		
Email:	damionnenobles@mvalaw.com, jansnider@mvalaw.com, vangambrell@mvalaw.com		
Correspondent Name:	MOORE & VAN ALLEN PLLC		
Address Line 1:	100 NORTH TRYON STREET, SUITE 4700		
Address Line 2:	ATTN: IP DEPARTMENT		
Address Line 4:	CHARLOTTE, NORTH CAROLINA 28202		
ATTORNEY DOCKET NUMBER:	036251-000526 CALLID-ATHY		
NAME OF SUBMITTER:	JAMES VAN CLEAVE GAMBRELL		
SIGNATURE:	/James Van Cleave Gambrell/		
DATE SIGNED:	12/29/2023		

Total Attachments: 4

source=IP_Notice-Patents-Calliditas_Therapeutics-Athyrium_Opportunities#page1.tif

source=IP_Notice-Patents-Calliditas_Therapeutics-Athyrium_Opportunities#page2.tif

source=IP_Notice-Patents-Calliditas_Therapeutics-Athyrium_Opportunities#page3.tif

source=IP_Notice-Patents-Calliditas_Therapeutics-Athyrium_Opportunities#page4.tif

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to the U.S. Security Agreement dated as of December 27, 2023 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”) by and among the Grantors party thereto (each a “Grantor” and collectively, the “Grantors”) and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent (the “Administrative Agent”) for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the patents, patent licenses and patent applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the patents, patent licenses and patent applications set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement, (ii) is not to be construed as an assignment of any patent, patent license or patent application.

This Notice of Grant of Security Interest in Patents and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating hereto and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the law of the State of New York.

[Signature pages follow]

Very truly yours,

CALLIDITAS THERAPEUTICS AB (publ),
a Swedish public limited liability company with Swedish
registration number 556659-9766

By: 

Name: Rene Aguiar Lucander

Title: Chief Executive Officer

Acknowledged and Accepted:

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES IV CO-INVEST I LP,
a Delaware limited partnership

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV
CO-INVEST LLC, its General Partner

By: _____

Name:

Title:

CALLIDITAS THERAPEUTICS AB
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS

PATENT
REEL: 065984 FRAME: 0542

Very truly yours,

CALLIDITAS THERAPEUTICS AB (publ),
a Swedish public limited liability company with Swedish
registration number 556659-9766


By: _____
Name:
Title:

Acknowledged and Accepted:

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP,
a Delaware limited partnership

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV
CO-INVEST LLC, its General Partner

By:  _____
Name: Rashida Adams
Title: Authorized Signatory

Schedule 1

Patents:

Patents and Patent Applications co-owned by CALLIDITAS THERAPEUTICS AB and KYOWA KIRIN SERVICES LTD.:

Country	Appl. No. (Appl. Date)	Publ. No. (Publ. Date)	Status (Grant Date)	Patent No.
PCT	PCT/GB2009/001150 (7 May 2009)	WO2009138716 (19 Nov 2009)	National phase entered	
US	12/992182 (7 May 2009)	2011-0104269 (5 May 2011)	Granted (23 Jul 2013)	8491932

Patents and Patent Applications owned exclusively by CALLIDITAS THERAPEUTICS AB:

Country	Appl. No. (Appl. Date)	Publ. No. (Publ. Date)	Status (Grant Date)	Patent No.	Title
US	63/302226 (24 Jan 2022)		Lapsed		New Pharmaceutical Compositions
US	63/302216 (24 Jan 2022)		Lapsed		New Pharmaceutical Compositions
PCT	PCT/EP2023/051680 (24 Jan 2023)	WO 2023/139285 (27 Jul 2023)	Pending		Pharmaceutical compositions comprising budesonide for treating IGA nephropathy
US	18/100396 (23 Jan 2023)	2023-0293444 (22 Sep 2023)	Allowed		New Pharmaceutical Compositions
UScon1	18/352811 (14 Jul 2023)		Pending		New Pharmaceutical Compositions